Phase III Study of Idelalisib and Rituximab for Previously Treated CLL


Phase III Study of Idelalisib and Rituximab for Previously Treated CLL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Furman RR et al. A Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Proc ASH 2013;Abstract LBA-6.

Furman RR et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;[Epub ahead of print]. Abstract

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.